Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

ConclusionsThus far, three CDK 4/6 inhibitors —palbociclib, ribociclib, and more recently, abemaciclib—have been approved for use in the setting of HR+, HER2−, mBC.  The degrees to which these agents differ in terms of CDK4/6 affinity, side-effect profiles, dosing, degree of central nervous system (CNS) penetration, optimal use in combin ation with antiestrogen therapy, and across other subsets of breast cancer, remain an active area of investigation.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research